128
Participants
Start Date
February 15, 2018
Primary Completion Date
September 1, 2019
Study Completion Date
June 1, 2020
Empagliflozin at a dose of 10 mg/day
Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
Rambam Health Care Campus
OTHER